Otoharmonics announces US patent approval for unique elements of their Levo tinnitus system.
Utilizing an FDA-cleared neuroscience-based approach, the Levo System offers a patented method to provide personalized sound therapy while sleeping.
"This is a significant advancement in tinnitus care," said Michael Baker, CEO and President of Otoharmonics. "Patent approval reinforces what we already know: The Levo System stands apart from every other tinnitus therapy on the market."
Unlike other tinnitus therapies, only the Levo System:
Is specifically designed for use during sleep
Has a patented sound matching method to identify a patient’s unique tinnitus sound
Offers the ability to hear what patients hear and develop truly personalized therapy
Can track patient use and response to therapy using a patented method leveraging smart technology
Exclusively integrates the Tinnitus Functional Index (TFI) to measure and monitor tinnitus impact on quality of life
Is FDA-cleared as a medical device using Apple hardware and proprietary software
Has high fidelity custom-fit ear buds
Otoharmonics is a privately held company with headquarters in Portland, Oregon USA. An international team of world-class neuroscientists, clinicians, business professionals and patients, Otoharmonics has developed the patented Levo System for the management of tinnitus symptoms.
With a personal approach and a deep understanding of the impact tinnitus can have, Levo is designed to be user-friendly and capable of delivering custom sound therapy based on the specific needs of the individual.